FindTrial
Sign In

Specific post-marketing surveillance of garenoxacin (Geninax)

Specific post-marketing surveillance of garenoxacin (Geninax) Clinical efficacy and safety of garenoxacin in the treatment of legionella pneumonia

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222731
Enrollment
20
Registered
2015-01-29
Start date
2015-01-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Legionella pneumonia

Interventions

investigational material(s) Generic name etc : Garenoxacin 200 mg tablet INN of investigational material : Garenoxacin Therapeutic category code : 624 Synthetic antibacterials Dosage and Administratio

Sponsors

Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Registered patients in Japanese Society of Chemotherapy the committee of evaluation of legionella pneumonia on or after May 7, 2008

Exclusion criteria

Exclusion criteria: 1.Patients with a history of hypersensitivity to any of the ingredients of this product or quinolone antibacterial agents. 2.Pregnant women or women who may become pregnant 3.Children

Design outcomes

Primary

MeasureTime frame
Efficacy 1.Evaluation of therapy 2.Evaluation of preventing reactivation—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026